The Women's Tennis Association (WTA) will require genetic testing for players, checking for the presence of the SRY gene in order to compete.

The Women's Tennis Association (WTA) will implement a new policy that will require all players to undergo genetic testing in order to compete on the WTA circuit. According to this policy, which will come into effect on Tuesday, players will need to provide a saliva or blood sample to check for the presence of the SRY gene, associated with male characteristics. Testing will be done once in a lifetime, and a negative result will allow players to compete. In the case of a positive result, they will require additional medical evaluations. The previous policy allowed transgender women to compete if they maintained their testosterone levels below 2.5 nmol/L for two years. The WTA emphasizes that the new policy is intended to promote equal opportunities in women's tennis and ensure fair competition. The change comes after other sports organizations, such as World Athletics and World Boxing, have adopted similar regulations regarding genetic testing. The WTA is committed to treating all players with dignity in the implementation of this sensitive policy.